[ad_1]
Westport, CT, Nov. 17, 2021 (GLOBE NEWSWIRE) – BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company that markets an innovative signal processing platform for signal enhancement, fidelity and detection of the entire Spectrum of EKG and intracardiac signals, today announced its participation in The Benchmark Company’s 10th Annual Discovery One on One Investor Conference (virtual) on Thursday, December 2nd, 2021.
The company’s management will provide a business update on the launch of its FDA 510 (k) cleared medical device, the PURE EP ™ System, which aims to increase procedural efficiency and effectiveness in cardiac electrophysiology and prioritize key priorities for outline the next phase of its commercial and clinical growth. To date, 73 physicians have completed over 1700 patient cases using the PURE EP ™ System. The company is in a focused commercial rollout of the PURE EP ™ system in Northeast Texas and Florida. The technology is regularly used in some of the top-tier hospitals in the country, including St. David’s Medical Center in Austin, TX, the Mayo Clinic in Florida, Minnesota, and Arizona, and the University of Pennsylvania in Philadelphia, PA. The company recently completed its first clinical study and is hosting a round table to discuss the results. The event, led by the three industry experts, will take place on November 18, 2021 at 8 p.m. ET.
The Benchmark Company 10th Annual Discovery One on One Investor Conference
Date: Thursday, December 2, 2021
Time: 8:00 am – 4:00 pm EST
For parties interested in arranging a one-on-one meeting with BioSig management, please contact the conference coordinators at: events@benchmarkcompany.com
About the Benchmark Company Discovery Conference
The annual Benchmark Company Discovery Conference is hosted by The Benchmark Company, a boutique investment bank with headquarters in New York and regional offices across the country. Benchmark offers listed and private companies, institutional and wealthy investors as well as family offices research, sales, trading and investment banking. The conference is regularly attended by more than 150 institutional investors and includes around 50 presenting companies.
The story goes on
About BioSig technologies
BioSig Technologies is a medical technology company that markets a proprietary biomedical signal processing platform designed to improve signal fidelity and reveal the full spectrum of EKG and intracardiac signals (www.biosig.com).
The company’s first product, the PURE EP ™ System, is a computerized system for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology in an EP laboratory Subject to procedure (EP).
Forward-Looking Statements
This press release contains “forward-looking statements”. Such statements may be preceded by the words “intends”, “can”, “will”, “plan”, “expect”, “anticipate”, “project”, “predict”, “estimate”, “aim”, “believe” “,“ Hopes ”,“ potentially ”or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company and cannot be predicted or quantified, and consequently actual results could differ materially that are expressly or implicitly contained in such forward-looking statements. These risks and uncertainties include, without limitation, risks and uncertainties related to (i) the geographic, social, and economic impact of COVID-19 on our ability to run our business and raise capital when needed; (ii) our inability , manufacture our products and product candidates on a commercial scale either by ourselves or in collaboration with third parties; (iii) difficulties in obtaining finance on economically reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more officers or scientists; and (vi) difficulties in obtaining regulatory approval to market our products and product candidates. More detailed information about the company and the risk factors that may affect the realization of any forward-looking statements are included in the company’s filings with the Securities and Exchange Commission (SEC), including the company’s annual report on Form 10-K and its quarterly reports on Form 10-Q. Investors and security holders are strongly encouraged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or for any other reason.
CONTACT: Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 55 Greens Farms Road Westport, CT 06880 aballou@biosigtech.com 203-409-5444, x133
[ad_2]
https://finance.yahoo.com/news/biosig-participate-benchmark-company-10th-144500152.html
